Clearside Biomedical, Inc. (CLSD)
| Market Cap | 63.33M |
| Revenue (ttm) | 3.76M |
| Net Income (ttm) | -30.81M |
| Shares Out | 77.71M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 121,711 |
| Open | 0.8300 |
| Previous Close | 0.8123 |
| Day's Range | 0.8100 - 0.8395 |
| 52-Week Range | 0.7001 - 1.6500 |
| Beta | 2.05 |
| Analysts | Strong Buy |
| Price Target | 4.75 (+482.82%) |
| Earnings Date | Aug 11, 2025 |
About CLSD
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) ... [Read more]
Financial Performance
In 2024, Clearside Biomedical's revenue was $1.66 million, a decrease of -79.77% compared to the previous year's $8.23 million. Losses were -$34.35 million, 5.75% more than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CLSD stock is "Strong Buy." The 12-month stock price target is $4.75, which is an increase of 482.82% from the latest price.
News
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase ...
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum
ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexibl...
Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
Strong Clinical Evidence Supports Use of the Suprachoroidal Platform in Expanding the Standard of Care for the Treatment of Multiple Macular Diseases Strong Clinical Evidence Supports Use of the Supra...
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the...
Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference
ALPHARETTA, Ga., May 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...
Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer Ch...
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS ® (XIPERE ®) for Uveitic Macular E...
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector ® Provides Targeted and Compartmentalized Delivery of Therapeutics Dir...
Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development -
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025
ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to t...
Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
- CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD - - Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Ty...
Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
ALPHARETTA, Ga., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to th...
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design - - BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 T...
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
- ARCATUS ® , Branded as XIPERE ® in the U.S., is the First Globally Approved Suprachoroidal Therapy -
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina Society Congress Highlighting Clearside's...
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer...
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - - Agreement Provides Additional Validation for Clearside's Suprachoroidal Space (SCS...
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
ALPHARETTA, Ga., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors
ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
ALPHARETTA, Ga., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s...